Genetic Modulation of PPARγ Phosphorylation Regulates Insulin Sensitivity  by Rangwala, Shamina M. et al.
Developmental Cell, Vol. 5, 657–663, October, 2003, Copyright 2003 by Cell Press
Genetic Modulation of PPAR Phosphorylation
Regulates Insulin Sensitivity
is the master regulator of adipogenesis in vitro and in
vivo (Rosen and Spiegelman, 2001). Thiazolidinedione
(TZD) ligands for PPAR effectively ameliorate insulin
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Jason K. Kim,4 Gerald I. Shulman,4
Klaus H. Kaestner,2,3 and Mitchell A. Lazar1,2,3,* resistance and are used clinically to improve type 2
diabetes (Olefsky and Saltiel, 2000).1Division of Endocrinology, Diabetes,
and Metabolism The mechanism by which TZD-mediated activation of
PPAR improves insulin sensitivity in diabetes is un-Department of Medicine
2 Department of Genetics clear. In rodents and people, PPAR is most abundant
in adipose tissue (Chawla et al., 1994; Tontonoz et al.,3 The Penn Diabetes Center
University of Pennsylvania School of Medicine 1994), and the insulin sensitivity caused by treatment
with PPAR ligands occurs despite weight gain, whichPhiladelphia, Pennsylvania 19104
4 Departments of Internal Medicine, Cell Biology, generally predisposes to insulin resistance (Reginato
and Lazar, 1999). It has been difficult to determine fromand Cellular and Molecular Physiology and
Howard Hughes Medical Institute genetic models whether PPAR has effects on insulin
sensitivity that are independent of changes in adiposity.Yale University School of Medicine
New Haven, Connecticut 06510 Targeted ablation of the PPAR gene locus in mice re-
sults in early embryonic lethality (Barak et al., 1999;
Kubota et al., 1999; Rosen et al., 1999). Heterozygous
PPAR null mice have improved insulin tolerance andSummary
have been reported to be protected from diet-induced
obesity and insulin resistance, although this has notObesity-associated diabetes is epidemic in industrial-
ized societies. The nuclear receptor peroxisome prolif- been a consistent finding (Kubota et al., 1999; Miles et
al., 2000, 2003; Yamauchi et al., 2001a). Humans witherator-activated receptor  (PPAR) is highly ex-
pressed in adipose tissue and the presumed molecular a dominant-negative PPAR allele are severely insulin
resistant but also lipodystrophic (Savage et al., 2003).target for antidiabetic thiazolidinedione drugs that re-
verse insulin resistance but also promote weight gain. PPAR activity is regulated by MAP kinase phosphor-
ylation of serine 112, which reduces its transcriptionalPhosphorylation reduces the activity of PPAR in vitro,
but physiological relevance has not been demon- activity (Adams et al., 1997; Camp and Tafuri, 1997; Hu
et al., 1996). The implications of this posttranslationalstrated. We have studied mice homozygous for a mu-
tation (S112A) that prevents PPAR phosphorylation. modification of PPAR activity are significant, as various
growth factors and cytokines could affect transcrip-Surprisingly, the weights and adipose mass of PPAR-
S112A mice are not greater than wild-type. Remark- tional activation of numerous genes involved in lipid
metabolism via this pathway. However, the biologicalably, however, genetic prevention of PPAR phos-
phorylation preserves insulin sensitivity in the setting significance of PPARphosphorylation is not well under-
stood. Interestingly, a mutation that increases PPAR ac-of diet-induced obesity. Underlying this protection are
smaller fat cells, elevated serum adiponectin, and re- tivity by preventing phosphorylation has been found in
obese humans (Ristow et al., 1998). These individualsduced free fatty acid levels. Thus, the phosphorylation
state of PPAR modulates insulin sensitivity. Com- were reported to be morbidly obese with greater than
expected insulin sensitivity.pounds that prevent PPAR phosphorylation or ligands
that induce the conformation of nonphosphorylated To better understand the biological function of PPAR
phosphorylation, we have created a mouse in which thePPAR may selectively enhance insulin sensitivity
without increasing body weight. serine 112 codon has been changed to alanine. The
resulting mice do not manifest increased adiposity on
Introduction normal or high-fat chow, but are protected from insulin
resistance in the setting of diet-induced obesity. Re-
Obesity has become a major public health concern in markably, the genetic prevention of PPAR phosphory-
most industrialized societies (Friedman, 2003). Of partic- lation preserves insulin sensitivity in the setting of diet-
ular concern is the strong correlation between adiposity induced obesity. Underlying this protection are changes
and type 2 diabetes, as well as the “metabolic syn- in fat cell size, gene expression, and secreted factors
drome” associated with resistance to the actions of in- that are likely to contribute to the insulin sensitivity.
sulin. Adipose tissue is now recognized to be an endo-
crine organ, and fat-derived circulating factors such as
free fatty acids (FFA) and proteins such as leptin, adipo- Results and Discussion
nectin, resistin, TNF, and IL-6 all may contribute to
organismal insulin sensitivity (Ahima and Flier, 2000). A Mice with a serine-to-alanine substitution at codon 112
member of the nuclear hormone receptor superfamily, of PPAR2 were generated by homologous recombina-
peroxisome proliferator-activated receptor  (PPAR), tion (Figures 1A–1D). The resulting PPAR-S112A mu-
tant has been shown to be nonphosphorylatable and
more active than wild-type PPAR (Adams et al., 1997;*Correspondence: lazar@mail.med.upenn.edu
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Figure 1. Generation of PPAR-S112A Mice
(A) Schematic representation of PPAR.
(B) Targeting strategy for PPAR-S112A.
(C) ES cells with PPAR-S112A mutation. Southern analysis using the 3 probe shown in (B).
(D) PCR around remaining lox P site in tail DNA of mutant and wild-type mice.
(E) PPAR protein in white adipose tissue. Immunoblot analysis of PPAR after SDS-PAGE to separate PPAR1 and 2 isoforms, and
phosphorylated forms (Shao et al., 1998). Equal loading was confirmed by Ponceau S staining (not shown). Densitometry of multiple immunoblots
revealed no significant difference in the total amount of PPAR1 or PPAR2 protein between wild-type and PPAR-S112A.
Camp and Tafuri, 1997; Hu et al., 1996). Mice homozy- setting of diet-induced obesity (Figure 3A). In this model,
PPAR-S112A mice displayed reduced insulin levelsgous for the PPAR-S112A mutation were born at ex-
pected Mendelian frequencies, and adipose PPAR during a 4 hr fast (Figure 3B). Although blood glucose
was not significantly different (data not shown), the ho-mRNA (not shown) and protein (Figure 1E; see Supple-
mental Figure S1 at http://www.developmentalcell.com/ meostasis model assessment (HOMA) measure of insu-
lin sensitivity based on simultaneous glucose and insulincgi/content/full/5/4/657/DC1) are expressed at levels
comparable to wild-type. However, whereas wild-type determinations was lower in PPAR-S112A mice, sug-
gestive of increased insulin sensitivity (Figure 3C). In-PPAR exists in both phosphorylated and nonphos-
phorylated forms, PPAR-S112A is exclusively non- deed, insulin tolerance testing revealed the PPAR-
S112A mice to be more sensitive to insulin than wild-phosphorylated (Figure 1E).
PPAR-S112A mice were healthy and grew at a nor- type (Figure 3D). The PPAR-S112A mice were studied
on a high-fat diet under hyperinsulinemic euglycemicmal rate, with weights that were not distinguishable from
their wild-type littermates (Figure 2A). When challenged clamp conditions to better understand their preserved
insulin sensitivity. Notably, whole-body glucose uptakewith a high-fat diet, the weight gain of PPAR-S112A
mice was not significantly different from wild-type mice was 45% greater in PPAR-S112A mice (Figure 3E),
whereas no significant difference in hepatic glucose pro-(Figure 2A). The total body fat as assessed by dual-
energy X-ray absorptiometry (Figure 2B), as well as body duction was observed (data not shown). These findings
indicate that the insulin sensitivity of PPAR-S112A micefat distribution (not shown), was similar to their wild-
type littermates. In addition, no significant change in in the setting of diet-induced obesity was primarily the
result of increased whole-body glucose disposal, mostfood intake or oxygen consumption was observed in
PPAR-S112A mice (data not shown). quantitatively into muscle.
Adipocyte size correlates inversely with insulin sensi-On normal chow, the glucose tolerance and insulin
levels of PPAR-S112A mice were not distinguishable tivity, and has been shown to be reduced by TZD treat-
ment (Okuno et al., 1998). Adipocytes from PPAR-from those of wild-type mice (Supplemental Figure S2).
Remarkably, however, PPAR-S112A mice were signifi- S112A mice were visibly (Figure 4A) and quantitatively
(Figure 4B) smaller than wild-type. Because the adiposecantly more glucose tolerant than wild-type mice in the
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of resistin, a TZD-regulated adipocyte hormone whose
actions antagonize those of insulin (Rajala et al., 2003;
Steppan et al., 2001), were not altered significantly by
the PPAR-S112A mutation (data not shown).
Serum-free fatty acids (FFA) have also been linked to
insulin resistance (Boden and Shulman, 2002), and FFA
as well as triglyceride levels were significantly lower
than in wild-type mice (Figures 4G and 4H). TZDs also
reduce FFA levels, increasing flux into white adipose
tissue (WAT) by induction of genes such as lipoprotein
lipase (LPL) and fatty acid transport protein 1 (FATP1)
(Frohnert et al., 1999; Schoonjans et al., 1996), and in-
creasing fatty acid recycling within the adipocyte via
induction of PEPCK and glycerol kinase (GyK; Guan et
al., 2002; Tontonoz et al., 1995; Tordjman et al., 2003).
None of these genes were significantly increased in
PPAR-S112A mice, although there were nonsignificant
trends toward induction of adipose FATP1 (WT: 0.62 
0.14 [n  4]; S112A: 2.35  0.79 [n  8]; p  0.16) and
GyK mRNA (WT: 0.65  0.09 [n  4]; S112A: 1.01 
0.81 [n  8]; p  0.76). The relatively minor changes in
expression of TZD-inducible genes involved in adipo-
cyte lipid metabolism may explain why the PPAR-
S112A mutation led to modestly reduced serum FFA but
no significant weight gain. Indeed, changes in serum
FFA and triglycerides in PPAR-S112A mice may be
related to elevated levels of adiponectin, which have
been shown to increase FFA oxidation and predispose
to weight loss (Fruebis et al., 2001; Yamauchi et al.,
2001b). Although brown adipose tissue (BAT) also ex-
presses PPAR (Tontonoz et al., 1994), no significant
Figure 2. Weight and Body Fat of PPAR-S112A Mice difference in BAT weight, histology, or expression of
UCP-1 was observed (Supplemental Figure S3).(A) Body weights of PPAR-S112A and wild-type littermate mice on
normal chow or on a high-fat diet. A 45% kcal fat diet (Research We conclude that inheritance of two nonphosphoryla-
Diets, D12451) was begun at 5 weeks of age. Shown are means  table PPAR alleles does not produce or exacerbate
standard error. On normal chow, n  7, PPAR-S112A; n  9  11, obesity in mice. Although heterozygosity for a nonphos-
wild-type; on high-fat chow, n  8, PPAR-S112A; n  7  8,
phorylatable PPAR allele has been described in fourwild-type.
unrelated obese German patients, no genetic linkage(B) Percent body fat of control and mutant mice measured by DEXA
has been observed and no additional patients with thisafter 19 weeks on a high-fat diet. n  8, PPAR-S112A; n  7,
wild-type. allele have been found in the German population (Hamer
et al., 2002). The phenotype of the homozygous mutant
mice, together with the absence of any genetic linkage
mass was not different, this implies that the total number or causal connection between the human polymorphism
of adipocytes was increased by the PPAR-S112A mu- and obesity, cast doubt as to whether heterozygosity
tation, consistent with its enhanced adipogenic capacity for a nonphosphorylated PPAR variant would be suffi-
in cultured adipocytes (Hu et al., 1996; Shao et al., 1998) cient to cause obesity in humans.
as well as in fibroblasts from these mice (Figure 4C). Importantly, however, our data show that elimination
Along with these changes in adipocyte proliferation and of PPAR phosphorylation protects mice from diet-
size, PPAR-S112A mice manifest changes in several induced insulin resistance and glucose intolerance.
serum adipocyte-secreted factors associated with insu- Thus, phosphorylation modulates PPAR function in
lin sensitivity. Notably, serum levels of the adipocyte- vivo. The absence of phosphorylation of PPAR in-
derived insulin sensitizing hormone adiponectin were creases its activity, most likely by increasing its affinity
significantly increased in PPAR-S112A mice (Figure for an endogenous ligand such as 12, 14-15-deoxy-
4D). Consistent with this, adiponectin gene expression prostaglandin J2, or a related compound (Forman et
was increased in adipose tissue from PPAR-S112A al., 1995; Kliewer et al., 1995; Shao et al., 1998) and/or
mice (Figure 4E), although the magnitude of the changes increasing the ligand-independent constitutive activity
in adiponectin gene expression and serum levels was of its N-terminal transactivation domain (Adams et al.,
different, as has been observed in other models (Combs 1997; Castillo et al., 1999). Although MAP kinases effi-
et al., 2003). By contrast, serum levels of leptin, which ciently phosphorylate PPAR at serine 112 in vitro and
may promote insulin sensitivity (Shimomura et al., 1999), after exposure of cultured adipocytes to growth factors
were reduced in PPAR-S112A mice (Figure 4F). Both (Camp and Tafuri, 1997; Hu et al., 1996; Shao et al.,
the increase in adiponectin and decrease in leptin are 1998; Zhang et al., 1996), the identity of the physiological
consistent with the effects of TZDs (Combs et al., 2002; kinase for PPAR is not known. The phenotype of
PPAR-S112A mice suggests that inactivation of thisDeVos et al., 1996; Kallen and Lazar, 1996). Serum levels
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Figure 3. PPAR-S112A Mice Are Protected from Obesity-Induced Insulin Resistance
(A) Glucose tolerance test. Mice were fed a high-fat diet for 8 weeks prior to testing. Data presented are means  standard error (n  11,
wild-type; n  19, PPAR-S112A). *p  0.05.
(B) Insulin levels of PPAR-S112A and wild-type mice after a 4 hr fast. *p  0.05.
(C) HOMA-IR index of insulin sensitivity (insulin [pg/ml] 	 mM glucose). Serum was collected from mice on a high-fat diet for 5 weeks, fasted
for 4 hr beginning at 0800. n  15, wild-type; n  22, PPAR-S112A mutants. Data are presented as means  standard error. *p  0.05 by
Student’s t test.
(D) Insulin tolerance test. Mice were fed a high-fat diet for 11 weeks prior to testing. Data presented are means  standard error (n  4, wild-
type; n  11, PPAR-S112A). For both glucose and insulin tolerance tests, data were analyzed by repeated measures ANOVA followed by
posthoc tests using Statview software. *p  0.05.
(E) Whole-body glucose uptake. Mice were fed a high-fat diet for 4 weeks, and then hyperinsulinemic euglycemic clamps were performed for
120 min as previously described; n  6 mice for both groups. Data are presented as means  standard error. Comparisons between
experimental groups were performed using two-tailed, unpaired Student’s t test. *p  0.05.
kinase would lead to insulin sensitization without excess attributable to the nonphosphorylated form of PPAR
is primarily due to increased glucose disposal, mostweight gain.
The inherited preservation of insulin sensitivity without likely to muscle (Inzucchi et al., 1998). Intriguingly, how-
ever, TZD-responsive adipocyte genes regulating lipidaltered adiposity in PPAR-S112A mice constitutes
strong genetic proof that PPAR contributes directly to metabolism such as PEPCK and lipoprotein lipase were
not significantly increased in PPAR-S112A mice. Thus,glucose homeostasis in vivo. Mice heterozygous for a
PPAR null allele are also insulin sensitive, possibly due altered PPAR activity due to the modulation of its phos-
phorylation state may be qualitatively different than TZDto increased leptin levels (Kubota et al., 1999; Yamauchi
et al., 2001a). By contrast, the PPAR-S112A mice have treatment. As PPAR-S112A mice are protected from
insulin resistance without excess weight gain, com-elevated adiponectin levels but reduced leptin levels,
suggesting a different mechanism of insulin sensitiza- pounds that bind to PPAR to induce the conformation
of the nonphosphorylated receptor might have thera-tion. The increased adiponectin in PPAR-S112A mice
is likely to be a direct effect of the mutation in adipose peutic value as selective PPARmodulators, or SPPARMs
(Rocchi et al., 2001).tissue, where PPAR is most highly expressed. Smaller
adipocyte size and reduced serum FFA may also be
direct adipocyte effects of nonphosphorylated PPAR, Experimental Procedures
or could be secondary to the increase in adiponectin.
Generation of MiceInsulin sensitization by TZDs requires adipose tissue
A 129SvEv BAC library was screened by PCR and a PPAR BAC(Chao et al., 2000), and is similarly associated with in-
clone was isolated, mapped by restriction digests, and partially
creased adiponectin, decreased FFA, and smaller adi- sequenced. The serine 112 residue in exon 2 was mutated to an
pocytes (Combs et al., 2002; Oakes et al., 1997; Okuno alanine (S112A), using overlap PCR, and the mutated sequence was
used to construct a targeting vector containing exon 2 in the 5et al., 1998). Like TZD treatment, insulin sensitization
PPAR Phosphorylation and Insulin Sensitivity
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Figure 4. Morphologic and Biochemical Changes in PPAR-S112A Mice
(A and B) Smaller adipocyte size in PPAR-S112A mice. Adipocyte morphology (H-E stain).
(B) Adipocyte cell size was measured on dark-field images of paraformaldehyde-fixed sections of epidydymal adipose tissue as described in
Experimental Procedures. Data are presented as means  standard error. Five hundred-forty adipocytes from three wild-type mice and 610
adipocytes from five PPAR-S112A mice were analyzed after mice were fed a high-fat diet for 18 weeks. Data were analyzed using unpaired,
two-tailed Student’s t test. *p  0.02.
(C) Increased adipogenesis of MEFs from PPAR-S112A mice. Oil Red O staining.
(D) Serum adiponectin levels. Mice were fed a high-fat diet for 19 weeks (n  7, wild-type; n  8, PPAR-S112A).
(E) Adiponectin gene expression in epidydymal white adipose tissue, with wild-type normalized to 100% (n  4, wild-type; n  8, PPAR-
S112A). *p  0.005.
(F) Serum leptin levels. Mice were fed a high-fat diet for 3 weeks (n  15, wild-type; n  22, PPAR-S112A). Shown are means  standard
error. *p  0.05, Student’s t test.
(G and H) Serum-free fatty acid (G) and triglyceride (H) levels. Mice were fed a high-fat diet for 4 weeks (n  15, wild-type; n  22, PPAR-
S112A). Data are presented as means standard error. Comparisons between experimental groups were performed using two-tailed, unpaired
Student’s t test. *p  0.05.
homology arm. The targeting vector contains a floxed pGK-neor Blood Collection and Serum Measurements
Blood samples were collected from mice between 0900 hr and 1200and thymidine kinase (neo-tk) cassette. The targeting vector was
introduced into mouse TL-1 embryonic stem cells by electroporation hr and were incubated on ice for 30 min before being centrifuged
at 20,000 	 g to separate the serum. Serum was stored at 80
Cand the cells were subjected to selection under G418. Homologous
recombinants were identified using PCR and confirmed by Southern before use, and repeated freeze-thaw cycles were avoided on the
samples. Serum FFA and triglyceride measurements were per-blotting. Targeted lines were expanded and electroporated with a
Cre recombinase expression vector to delete the neo-tk cassette. formed using kits from Wako Chemicals and Sigma, respectively.
Serum insulin and leptin were measured using ELISA kits from Crys-The cells were then subjected to a gancyclovir selection and their
genotype was confirmed by PCR as well as by Southern blotting. talChem. Adiponectin was measured using a radioimmunoassay
from Linco Research.These clones were injected into blastocysts and resulting male chi-
meras were mated with female C57Bl6 mice. Germline transmission
was confirmed by agouti coat color and PCR. F1 mice were interbred Glucose and Insulin Tolerance Tests
For glucose tolerance tests, animals were fasted overnight fromto obtain mice on a mixed 129SvEV/C57BL6 background. These
mice were then interbred to obtain mice for experiments. Mice were 1700 hr to 0900 hr the next day. Basal blood glucose was measured
using an Accuchek Advantage glucometer (Roche Diagnostics). Ani-housed in an environmentally controlled mouse facility with a 12 hr
light-dark cycle. The Institutional Animal Care and Use Committee mals were then injected intraperitoneally with a bolus of glucose
(2 g/kg), and blood glucose levels were measured at 15, 30, 60, 90,of the University of Pennsylvania approved all animal experiments
performed. The mice were put on a 45% kcal fat diet (Research and 120 min. For insulin tolerance tests, animals were fasted for
5 hr, from 0900 hr to 1400 hr. Mice were injected intraperitoneallyDiets, D12451) at the age of 5 weeks. Animals were weighed on a
weekly basis. Analysis of body composition was performed using with a 0.5 U/kg of recombinant human insulin (Humulin), and blood
glucose levels were measured at 15, 30, 60, 90, and 120 min.a Piximus dual-energy X-ray absorptiometry scanner (GE).
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Whole-Body Glucose Uptake Studies Castillo, G., Brun, R.P., Rosenfield, J.K., Hauser, S., Park, C.W.,
Troy, A.E., Wright, M.E., and Spiegelman, B.M. (1999). An adipogenicMice were fed a high-fat diet for a period of 4 weeks, after which
hyperinsulinemic euglycemic clamps were performed for 120 min cofactor bound by the differentiation domain of PPAR. EMBO J.
18, 3676–3687.as previously described (Kim et al., 2001).
Chao, L., Marcus-Samuels, B., Mason, M.M., Moitra, J., Vinson, C.,
Adipocyte Morphology Studies Arioglu, E., Gavrilova, O., and Reitman, M.L. (2000). Adipose tissue
Dark-field images of paraformaldehyde-fixed sections of epidydy- is required for the antidiabetic, but not for the hypolipidemic, effect
mal adipose tissue were quantitated as described (Chen and Farese, of thiazolidinediones. J. Clin. Invest. 106, 1221–1228.
2002), except IP Lab software was used (Scanalytics).
Chawla, A., Schwarz, E.J., Dimaculangan, D.D., and Lazar, M.A.
(1994). Peroxisome proliferator-activated receptor  (PPAR): adi-
MEF Adipogenesis Assay
pose predominant expression and induction early in adipocyte dif-
Day 13.5 embryos were homogenized by passage through a 181/2
ferentiation. Endocrinology 135, 798–800.
gauge needle, and then plated out on a 10 cm tissue culture dish
Chen, H.C., and Farese, R.V., Jr. (2002). Determination of adipocyteand passaged when confluent. Experiments were performed on cells
size by computer image analysis. J. Lipid Res. 43, 986–989.that were passage 4–8. Two days past confluence, cells were incu-
bated with DMEM containing 10% FBS, insulin (10 g/ml), isobutyl- Combs, T.P., Wagner, J.A., Berger, J., Doebber, T., Wang, W.J.,
methylxanthine (0.5 mM), dexamethasone (1 M), and rosiglitazone Zhang, B.B., Tanen, M., Berg, A.H., O’Rahilly, S., Savage, D.B., et
(1 M). This was considered day 0 of differentiation. On day 2 and al. (2002). Induction of adipocyte complement-related protein of 30
every 2 days thereafter, the medium was changed to DMEM con- kilodaltons by PPAR agonists: a potential mechanism of insulin
taining 10% FBS, insulin (10 g/ml), and rosiglitazone (1 M). The sensitization. Endocrinology 143, 998–1007.
experiments were ended at day 7, and cells were harvested for RNA
Combs, T.P., Berg, A.H., Rajala, M.W., Klebanov, S., Iyengar, P.,
or stained with Oil Red O.
Jimenez-Chillaron, J.C., Patti, M.E., Klein, S.L., Weinstein, R.S., and
Scherer, P.E. (2003). Sexual differentiation, pregnancy, calorie re-
Gene Expression Studies striction, and aging affect the adipocyte-specific secretory protein
RNA from tissues was isolated using Trizol reagent (Life Technolo- adiponectin. Diabetes 52, 268–276.
gies). Northern blots were performed as described (Chawla et al.,
DeVos, P., Lefebvre, A.M., Miller, S.G., Guerre-Millo, M., Wong, K.,1994).
Saladin, R., Hamann, L.G., Staels, B., Briggs, M.R., and Auwerx, J.
(1996). Thiazolidinediones repress ob gene expression in rodentsStatistical Analysis
via activation of peroxisome proliferator-activated receptor . J.Data are presented as means SEM. Comparisons between experi-
Clin. Invest. 98, 1004–1009.mental groups were performed using two-tailed, unpaired Student’s
Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M.,t test. In the case of glucose and insulin tolerance tests, data were
and Evans, R.M. (1995). 15-deoxy, 12, 14-prostaglandin J2 is aanalyzed by repeated measures ANOVA followed by posthoc tests
ligand for the adipocyte determination factor PPAR. Cell 83,using Statview software.
803–812.
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